Understanding CA13: A Potential Drug Target for Lung Cancer (G377677)

Target Name: CA13

NCBI ID: G377677

CA13

Understanding CA13: A Potential Drug Target for Lung Cancer

Cancer of the alveolar ducts, commonly known as CA13, is a type of lung cancer that originates from the alveolar ducts, which are the small airways that carry mucus from the lungs to the trachea. This type of cancer is aggressive and has a poor prognosis, with a five-year survival rate of only around 20%.

Despite its poor prognosis, efforts to develop new treatments for CA13 have been ongoing for many years. One potential drug target for this cancer is the protein CA13 (CAH13_HUMAN), which is a glycoprotein that is expressed in the alveolar ducts of humans.

The CA13 protein is produced by the epithelial cells that line the alveolar ducts. It is a transmembrane protein that is involved in several physiological processes in the lungs, including the regulation of ion and water transport, as well as the production of mucus.

Recent studies have shown that the CA13 protein is involved in several processes that are associated with the development and progression of CA13 cancer. For example, studies have shown that CA13 is involved in the regulation of the cell cycle, and that it can inhibit the ability of cells to divide and proliferate.

In addition, CA13 has been shown to play a role in the development of resistance to chemotherapy inCA13 cancer. This is because the CA13 protein can interact with certain chemotherapy drugs, making it more difficult for these drugs to work effectively.

Another potential drug target for CA13 is the CA13 cell surface antigen (CA13-AS), which is a protein that is expressed on the surface of CA13 cells. This antigen is involved in several cellular processes, including cell adhesion, migration, and invasion.

Studies have shown that the CA13-AS protein is involved in the regulation of cell adhesion and that it can promote the migration and invasion of CA13 cells. This makes it a potential target for new treatments for CA13 cancer.

In conclusion, the CA13 protein is a potential drug target for CA13 cancer. Its involvement in several cellular processes that are associated with the development and progression of this disease makes it an attractive target for new treatments. Further research is needed to fully understand the role of the CA13 protein in the development and treatment of CA13 cancer.

Protein Name: Carbonic Anhydrase 13

Functions: Reversible hydration of carbon dioxide

The "CA13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CA13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets